Stockreport

Athenex Announces Acceptance of Phase II Data of KX2-391 for the Treatment of Actinic Keratosis for Presentation at the American Academy of Dermatology Meeting on February 17, 2018

Athenex, Inc.  (ATNX) 
Last athenex, inc. earnings: 2/27 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.athenex.com
PDF BUFFALO, N.Y., Nov. 28, 2017 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercial [Read more]